Navigation Links
Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
Date:10/11/2007

ZUG, Switzerland, October 11 /PRNewswire/ -- The young Swiss biotech enterprise AMVAC AG has gained reinforcement from Prof. Michel Klein, one of the world's most renowned vaccine specialists. Prof. Klein, who was formerly Vice President of Science & Technology of the Aventis-Pasteur Group, will immediately assume directorship of the scientific sector of vaccine development at AMVAC AG. This distinguished vaccinologist has access to an outstanding network across one of the greatest growth markets and will make a critical contribution in AMVAC AG's product research and development. Along with the vaccine against bacterial vaginosis already approved in Hungary, Klein is focusing on the further development of a vaccine against prostate enlargement, for which the performance of a clinical phase III study has been approved. In addition, AMVAC AG is preparing new projects for indications unnamed until now. Official statements on more new projects in the pharmaceutical industry will be released in the coming weeks.

Melinda Karpati, CEO of AMVAC, AG says, "Being able to win Prof. Michel Klein is a great success for us and affirms not only AMVAC AG's executive? direction, but also the continued recognition that we have come to know on the part of experienced experts in the field of vaccine development. His global network and the tremendous experience that Prof. Michel Klein brings to AMVAC AG will help us develop novel prophylactic and immunotherapeutic products in the pharmaceutical industry. Our new CSO's 40-year career has included numerous scientific publications, distinctions and groundbreaking vaccine developments. He has developed the five-component acellular pertussis vaccine currently on the market, brought vaccines against PIV-3, RSV and flu to phase I/II trials, launched the cancer vaccine program of Aventis-Pasteur and performed more than 40 trials with several prototypes of prophylactic and therapeutic HIV vaccines in collaboration with the NIH, WRAIR, Eurovac and the ANRS. He is the author of more than 350 patents in the fields of vaccinology, immunology, infectious diseases and biotechnology.

About AMVAC AG

AMVAC AG is a young biopharmaceutical company based in Switzerland that is concentrating in the high-yield pharmaceutical industry on an especially high-growth market segment. An average annual growth rate of 13% is forecast until 2010 for the vaccines market, compared with 6% for pharmaceuticals in general. AMVAC products are further characterized by meeting unfulfilled therapy requirements in the fields of urology and gynecology. AMVAC has to date licensed and further developed two advanced immunotherapeutic drugs with gold standard potential. Further products are in the planning stage.

Contact:

AMVAC AG

Ariane Meynert

Metallstrasse 4

6300 Zug

Switzerland

Phone: +41-41-725-32-30

Fax: +41-41-725-32-33

Mobile: +41-79-793-34-19 / +49-172-775-92-12

E-Mail:meynert@amvac.ch


'/>"/>
SOURCE AMVAG AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Safe Internet requires total network security, prof. says
2. Daugherty becomes CTO of Great Lakes BioFuels
3. DataPod becomes BeInSync so you can, too
4. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
5. Historic observatory becomes hot property on Lake Geneva
6. State technology chief endorses IT audit recommendations
7. Fusion 2007: CA chief says IT complexity raises risk
8. Web-Based Learning Developed under new Chief Education Officer
9. UW-Madisons Beebe wins scientific award
10. Researchers say scientific reporting needs more perspective, less hype
11. Wisconsin stands at the center of scientific efforts to avert flu epidemics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ., an ... tools, and market leader for Semantic Graph Database technology, today announced ... the most effective system for developing and deploying applications to solve the challenges ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Services and Metrology Partners.     , Covalent’s Analytical Services unit provides high-quality ... can be measured within 24 hours of receipt. There are no price premiums, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
Breaking Biology News(10 mins):